Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission WadeĪll Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Gilead Receives Complete Response Letter from U.S. Gilead Enables Easier Veklury® (Remdesivir) Access Through Retail and Specialty Pharmacies for Long-Term Care and Skilled Nursing Facilities Gilead Sciences Commends Convictions in Counterfeiting Scheme Pledges Continued Commitment to Protect Patients
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |